Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices 3163 

Contact Person: Ming Yan, MD, Ph.D., 

Scientific Review Officer, Immunology 

(IMM), DPPS, Center for Scientific Review, 

National Institutes of Health, 6701 Rockledge 

Drive, RM 4205, Bethesda, MD 20892, (301) 

594–0343, yanming@mail.nih.gov. 

Name of Committee: National Institute of 

Nursing Research Special Emphasis Panel; 

Fellowship and Career Development. 

Date: February 19, 2021. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Nursing 

Research, National Institutes of Health, 6701 

Democracy Boulevard, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Ming Yan, MD, Ph.D., 

Scientific Review Officer, Immunology 

(IMM), DPPS, Center for Scientific Review, 

National Institute of Nursing Research, 

National Institutes of Health, 6701 Rockledge 

Drive, RM 4205 Bethesda, MD 20892, (301) 

594–0343, yanming@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.361, Nursing Research, 

National Institutes of Health, HHS) 

Dated: January 8, 2021. 

Tyeshia Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00651 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

The meeting will be closed to the 

public as indicated below in accordance 

with the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended for the review, discussion, 

and evaluation of individual intramural 

programs and projects conducted by the 

NATIONAL INSTITUTE OF 

NEUROLOGICAL DISORDERS AND 

STROKE, including consideration of 

personnel qualifications and 

performance, and the competence of 

individual investigators, the disclosure 

of which would constitute a clearly 

unwarranted invasion of personal 

privacy. 

Name of Committee: Board of Scientific 

Counselors, National Institute of 

Neurological Disorders and Stroke. 

Date: April 11–13, 2021. 

Time: 3:00 p.m. to 12:00 p.m. 

Agenda: To review and evaluate personnel 

qualifications and performance, and 

competence of individual investigators. 

Place: Porter Neuroscience Research 

Center, Building 35A, 35 Convent Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Lorna W. Role, Ph.D., 

Scientific Director, Division of Intramural 

Research, National Institute of Neurological 

Disorders and Stroke, 35A Convent Drive, 

MSC 3716, Bethesda, MD 20892, lorna.role@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.853, Clinical Research 

Related to Neurological Disorders; 93.854, 

Biological Basis Research in the 

Neurosciences, National Institutes of Health, 

HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00653 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of CD33-Specific 

Chimeric Antigen Receptor (CAR) 

Therapies for CD33-Expressing 

Malignancies Using Natural Killer Cells 

(NK Cells) Transduced With Retroviral 

or Lentiviral Vectors 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this Notice to Senti Bio 

(‘‘Senti’’), located in South San 

Francisco, CA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before January 29, 2021 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Jim Knabb, Senior 

Technology Transfer Manager, NCI 

Technology Transfer Center at Email: 

jim.knabb@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

E–097–2018–0: Anti-CD33 Chimeric 

Antigen Receptors for Treatment of 

Human Acute Myeloid Leukemia 

1. US Provisional Patent Application 

62/643,015, filed March 14, 2018 

(E–097–2018–0–US–01); 

2. International Patent Application PCT/ 

US2019/022,309, filed March 14, 

2019 (E–097–2018–0–PCT–02) 

3. United Arab Emirates Application 

No: P6001291/2020, filed 

September 13, 2020 (E–097–2018– 

0–AE–03) 

4. Australia Application No: 

2019235926, filed September 2, 

2020 (E–097–2018–0–AU–04) 

5. Canada Application No: 3,093,567, 

filed September 9, 2020 (E–097– 

2018–0–CA–05) 

6. China Application No: 

201980018105.0, filed September 9, 

2020 (E–097–2018–0–CN–06) 

7. Eurasia Application No: 202092044, 

filed September 25, 2020 (E–097– 

2018–0–EA–07) 

8. European Patent Application No: 

19714007.2, filed October 14, 2020 

(E–097–2018–0–EP–08) 

9. Israel Application No: 277078, filed 

September 1, 2020 (E–097–2018–0– 

IL–09) 

10. India Application No: 

202047039152, filed September 10, 

2020 (E–097–2018–0–IN–10) 

11. South Korea Application No: 2020– 

7029302, filed October 13, 2020 (E– 

097–2018–0–KR–11) 

12. Mexico Application No: MX/a/2020/ 

009472, filed September 10, 2020 

(E–097–2018–0–MX–12) 

13. New Zealand Application No: 

767782, filed September 13, 2020 

(E–097–2018–0–NZ–13) 

14. Saudi Arabia Application No: 

520420134, filed September 13, 

2020 (E–097–2018–0–SA–14) 

15. Singapore Application No: 

11202008796V, filed September 9, 

2020, (E–097–2018–0–SG–15) 

16. United States of America 

Application No: 16/980,205, filed 

September 11, 2020 (E–097–2018– 

0–US–16) 

17. South Africa Application No: 2020/ 

05571, filed September 8, 2020 (E– 

097–2018–0–ZA–17) 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

fields of use may be limited to the 

following: 

An exclusive license to: 

1. The development of a CD33- 

specific logic-gated CAR-based 


khammond on DSKJM1Z7X2PROD with NOTICES
3164 Federal Register / Vol. 86, No. 9 / Thursday, January 14, 2021 / Notices 

immunotherapy using autologous 

human T cells transduced with 

lentiviral vectors, wherein the viral 

transduction leads to the expression of 

a CAR that targets CD33 (comprised of 

the CD33-binding domain referenced as 

Hu195 or hP67.6 in the invention as 

well as an intracellular signaling 

domain), for the prophylaxis or 

treatment of CD33-expressing cancers. 

For clarity, ‘‘CD33-specific logic-gated 

CAR-based immunotherapy’’ means 

therapies where the CAR-expressing T 

cells recognize CD33 and are engineered 

to respond to one or more additional 

antigens (but not necessarily all of the 

antigens). 

2. The development of a CD33- 

specific logic-gated CAR-based 

immunotherapy using allogeneic human 

NK cells transduced with retroviral 

vectors, including but not limited to 

lentiviral vectors, wherein the viral 

transduction leads to the expression of 

a CAR that targets CD33 (comprised of 

the CD33-binding domain referenced as 

Hu195 or hP67.6 in the invention as 

well as an intracellular signaling 

domain), for the prophylaxis or 

treatment of CD33-expressing cancers. 

For clarity, ‘‘CD33-specific logic-gated 

CAR-based immunotherapy’’ means 

therapies where the CAR-expressing NK 

cells recognize CD33 and are engineered 

to respond to one or more additional 

antigens (but not necessarily all of the 

antigens). 

These technologies disclose therapies 

to treat AML by utilizing CARs that 

recognize AML cells through a binder 

for CD33. The CD33 binders are known 

as Hu195 or hP67.6. CD33 is a well 

validated immunotherapeutic target that 

is expressed on the surface of malignant 

cells, most notably on the surface of 

acute myelogenous leukemia (AML) 

blasts. 

This Notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published Notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: January 7, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–00637 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Production of Adjuvants 

Mimics (Topic 093) (For SBIRs Phase I) 

Date: February 1, 2021. 

Time: 11:00 a.m. to 1:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase I: Adjuvant Discovery for 

Vaccines and for Autoimmune and Allergic 

Disease (Topic 092) (For SBIRs Phase I). 

Date: February 1, 2021. 

Time: 1:30 p.m. to 2:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; HHS–NIH–CDC–SBIR PHS 

2021–1 Phase II: Adjuvant Discovery for 

Vaccines and for Autoimmune and Allergic 

Disease (Topic 092) (For SBIRs Phase II). 

Date: February 1, 2021. 

Time: 2:30 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20892 (Virtual Meeting). 

Contact Person: Maggie A. Morris Fears, 

Ph.D., Scientific Review Officer, Scientific 

Review Program, Division of Extramural 

Activities, National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3F52, 

Rockville, MD 20852, 301–761–5444, 

maggie.morrisfears@nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: January 8, 2021. 

Tyeshia M. Roberson, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–00573 Filed 1–13–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Neurological 

Disorders and Stroke; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 


khammond on DSKJM1Z7X2PROD with NOTICES